Ginkgo bioworks stock prediction.

The average price target for Ginkgo Bioworks Holdings is $3.50. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $7.00 ,the lowest forecast is $1.50. The average price target represents 144.76% Increase from the current price of $1.43.Ginkgo Bioworks Holdings (DNA – Research Report) received a Sell rating and a $1.25 price target from Goldman Sachs analyst Matthew Sykes today. The company’s shares closed yesterday at $1.68.Ginkgo Bioworks Holdings, Inc. (DNA) NYSE - Nasdaq Real Time Price. Currency in USD Follow 2W 10W 9M 1.4200 +0.1300 (+10.08%) As of 03:32PM EST. Market open. 1d 5d 1mEarnings for Ginkgo Bioworks are expected to grow in the coming year, from ($0.37) to ($0.30) per share. Ginkgo Bioworks has not formally confirmed its next …

Jason R. Kelly, who serves as the Director, CEO, and Founder of Ginkgo Bioworks Holdings, sold a total of 200,000 shares for $360,400. After this transaction, …

Oct 4, 2023 · Ginkgo Bioworks (DNA 8.53%) is a biotech unlike any other, and it's no surprise why it's consistently attracting the attention of bigwig portfolio managers like Cathie Wood. Wood's confidence in ...

Thinking about buying or selling stock in DNA? See the latest Ginkgo Bioworks Hldgs Inc (DNA) stock analysis, price, forecast, news and more.See the latest DNA Stock price for Ginkgo Bioworks Holdings Inc and NYSE: DNA stock rating, related news, valuation, dividends and more to help you make your investing decisions.Ginkgo Bioworks delivers some encouraging results. In January, Ginkgo released preliminary numbers for the full-year 2022 that indicated strong growth. The company expects its total revenue to ...Added 21 new Cell Programs to the Foundry platform in Q2 2023, representing 62% growth over the prior year period. Ginkgo's Cell Engineering segment generated services revenue, which does not ...Aug 11, 2023 · This week was one to forget for Ginkgo Bioworks ( DNA 5.80%) shareholders. In the Monday-to-Friday period, their investment lost slightly more than 8% of its value on the stock market, according ...

Ginkgo Bioworks. Ginkgo Bioworks investors can't seem to catch a break. The stock is trading lower in 2023's otherwise buoyant market, which follows a 63% drop last year.The latest step down came ...

What happened. Shares of Ginkgo Bioworks ( DNA 5.80%) were jumping 18.2% higher as of 10:58 a.m. ET. The nice gain came after the company announced its 2021 fourth-quarter and full-year results ...

The average analyst rating for DNA stock from 4 stock analysts is "Sell". This means that analysts believe this stock is likely to lead to lower returns than market …Ginkgo Bioworks Reports Second Quarter 2022 Financial Results. $145 million of Total revenue in Q2 2022, representing 231% growth over Q2 2021. 13 new Cell Programs added in Q2 2022, representing ...By John Blankenhorn, InvestorPlace Contributor Oct 7, 2023, 9:00 am EST. These biotech companies have invested in trials and tech to create a perfect launch for a breakout year. Gingko Bioworks ...The 7 analysts offering 12-month price forecasts for Ginkgo Bioworks Holdings Inc have a median target of 3.00, with a high estimate of 7.00 and a low estimate of 1.25.BOSTON, Sept. 27, 2023. BOSTON, Sept. 27, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with Pfizer (NYSE: PFE) focused on the discovery of RNA-based drug ...As the stock market is expected to remain under tremendous pressure in the near term, it could be wise to avoid fundamentally weak and overvalued Cathie Wood stocks Ginkgo Bioworks Holdings, Inc. (DNA), UiPath Inc. (PATH), Rocket Lab USA, Inc. (RKLB), and Verve Therapeutics, Inc. (VERV).Ginkgo Bioworks Holdings, Inc. ()DNA develops …Ginkgo Bioworks ( DNA ): It is an innovative biotech enterprise. The renowned investor and founder of Ark Invest, Cathie Wood, has set her sights on three disruptive growth stocks that may soon ...

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2021 Financial Results. $314 million of Total revenue in 2021, representing an increase of 309% over 2020. 31 new Cell Programs added in 2021 ...BOSTON and BASEL, Switzerland, March 14, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the entry into a definitive ...Mar 1, 2023 · Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results. $478 million of total revenue in 2022, representing an increase of 52% over 2021 and toward the high end of guidance ... r/ginkgobioworks: Subreddit for news & discussion of Ginkgo Bioworks — the organism company — $DNA — all welcome — free, frank, & diverse …Evgenii Kovalev. Ginkgo Bioworks (NYSE:DNA) is still finding its feet as a public company, with the stock continuing to decline on the back of valuation concerns and declining Biosecurity revenue ...Ginkgo Bioworks (DNA-7.19%) ... with a prediction for a 140% gain in the coming 12 months. ... whether you're looking at Ginkgo or another stock. Though Ginkgo shares may not take off overnight ...

Mar 30, 2022 · There are some variant perceptions on Ginkgo Bioworks Holdings, with the most bullish analyst valuing it at US$15.00 and the most bearish at US$6.00 per share. Note the wide gap in analyst price ... Ginkgo Bioworks. 15 Nov, 2022, 16:17 ET. BOSTON, Nov. 15, 2022 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"),which is building the leading platform for cell programing and ...

BOSTON and EMERYVILLE, Calif., Oct. 19, 2022 /PRNewswire/ -- Today, Ginkgo Bioworks ... common stock, 0.9179 shares of Ginkgo Class A ... are only predictions and involve known ...٣ ربيع الآخر ١٤٤٥ هـ ... Famous investor Cathie Wood has been buying up shares of Ginkgo Bioworks over the past year. The company's revenue has climbed in recent years, ...Why Ginkgo Bioworks isn't a Buffett stock today. Warren Buffett tends to invest in businesses that have highly consistent earnings, low-cost operations, and, above all, sustainable competitive ...r/ginkgobioworks: Subreddit for news & discussion of Ginkgo Bioworks — the organism company — $DNA — all welcome — free, frank, & diverse … 733.3157. 57.0849. -288.9. -6,916. Get the detailed quarterly/annual income statement for Ginkgo Bioworks Holdings, Inc. (DNA). Find out the revenue, expenses and profit or loss over the last ... 2. Ginkgo Bioworks. Ginkgo Bioworks (DNA 5.80%) is also a holding in the Ark Innovation ETF and the Ark Genomic Revolution ETF. The company is a leader in cell programming technology that's used ...Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results. $478 million of total revenue in 2022, representing an increase of 52% over 2021 and toward the high end of guidance ...

As the stock market is expected to remain under tremendous pressure in the near term, it could be wise to avoid fundamentally weak and overvalued Cathie Wood stocks Ginkgo Bioworks Holdings, Inc. (DNA), UiPath Inc. (PATH), Rocket Lab USA, Inc. (RKLB), and Verve Therapeutics, Inc. (VERV).Ginkgo Bioworks Holdings, Inc. ()DNA develops …

Ginkgo Bioworks (NYSE: ... Forward-looking statements are predictions, ... There’s still plenty of yield in the stock market even with the recent rally that has resulted in a 19% year-to-date ...

DNA Stock Price Prediction News Today 4 December - Ginkgo Bioworks HoldingsMay 10, 2023 · First quarter 2023 Total revenue of $81 million, down from $168 million in the comparable prior year period, a decrease of 52% driven by the expected ramp down of K-12 testing in Ginkgo's ... Nov 24, 2023 · Is Ginkgo Bioworks a stock worth buying? When the stock began trading in September 2021, its valuation was around $15 billion. Today, it has a market capitalization of just $3.2 billion. Ginkgo Bioworks Holdings stock price prediction is an act of determining the future value of Ginkgo Bioworks shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Ginkgo Bioworks' future price could yield a significant profit.Mar 30, 2022 · There are some variant perceptions on Ginkgo Bioworks Holdings, with the most bullish analyst valuing it at US$15.00 and the most bearish at US$6.00 per share. Note the wide gap in analyst price ... Ginkgo has some real cred. 15B enterprise value over 64M in revenue for 2020 gives us a 234 price-to-sales ratio. If we use their 59M GAAP revenue it's 254. Moderna's is 24. They're not peers, and this is a higher growth industry, but it seems like a massive differential nonetheless for a stock right out of the gate.About Ginkgo Bioworks. Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse ...Ginkgo Bioworks Holdings Inc’s trailing 12-month revenue is $315.0 million with a -272.3% profit margin. Year-over-year quarterly sales growth most recently was -16.6%. Analysts expect adjusted earnings to reach $-0.442 per share for the current fiscal year.There are some variant perceptions on Ginkgo Bioworks Holdings, with the most bullish analyst valuing it at US$15.00 and the most bearish at US$6.00 per share. Note the wide gap in analyst price ...Ginkgo Bioworks (DNA 10.85%) went public a few years ago. With sky-high expectations for growth spanning multiple industries, it may have been tempting for …Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, ... million (inclusive of stock-based compensation expense of $111 million), compared to Loss from ... Forward-looking statements are predictions, ...

Ginkgo Bioworks currently has 1 sell rating, 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DNA, but not buy more shares or sell existing shares.DNA Stock. USD 1.57 0.00 0.00%. Ginkgo Bioworks Holdings stock price prediction is an act of determining the future value of Ginkgo Bioworks shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Ginkgo Bioworks' future price could yield a ...Contact Us U.S. markets close in 28 minutes S&P 500 +26.05(+0.57%) Dow 30 +272.05(+0.76%) Nasdaq +74.18(+0.52%) Russell 2000 1,852.18 +43.16(+2.39%) Crude Oil 74.32 -1.64(-2.16%) Gold 2,089.10... Instagram:https://instagram. se stoclforex brokers listapex trader fundedbest dental insurance new york Sep 17, 2021 · Ginkgo Bioworks, a synthetic biology company now valued at around $15 billion, begins trading on the New York Stock Exchange today. Ginkgo’s market debut is one of the largest in biotech history. net and gross explainedrobinhood 24 hour trading The analysts covering Ginkgo Bioworks Holdings, Inc. delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for next year. Revenue and earnings per share (EPS) forecasts were both revised downwards, with analysts seeing grey clouds on the horizon.Sep 21, 2021 · So what. Initiating coverage on Ginkgo Bioworks, Sriharsha Pappu, an HSBC analyst, assigned a buy rating on the stock and a $14 price target. According to TheFly.com, Pappu believes that the ... vcpax Cathie Wood last bought Ginkgo stock on Aug. 21, but she's been a consistent buyer for quite some time now. Her position is worth around 2.7% of the portfolio, which makes it the 13th-largest holding.Real time Ginkgo Bioworks (DNA) stock price quote, stock graph, news & analysis.The analysts covering Ginkgo Bioworks Holdings, Inc. delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for next year. Revenue and earnings per share (EPS) forecasts were both revised downwards, with analysts seeing grey clouds on the horizon.